Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2018-11-05 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter from LASA Supergenerics Limited addressed to stock exchanges (BSE and NSE) notifying about an upcoming Board Meeting scheduled for November 14, 2018. The purpose of the meeting includes considering and approving unaudited financial results for the quarter and half year ended September 30, 2018, along with a Limited Review Report. It also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results or the Limited Review Report itself but is an announcement about the meeting where these will be considered. The document length is short (2601 characters) and it serves as an intimation or notice rather than the actual financial report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than an Interim Report (IR) or Earnings Release (ER).
2018-11-05 English
Shareholders meeting
Regulatory Filings
2018-09-26 English
AGM/Book Closure
AGM Information Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the submission of a published notice for the 3rd Annual General Meeting (AGM), including e-voting information and book closure dates. It mentions the remote e-voting period and the record date for voting, as well as the dates for the register of members and share transfer books closure. The document is short (2221 characters) and primarily serves as a notification or announcement about the AGM notice and related voting procedures. It does not contain the AGM materials themselves, nor detailed financial or management information. Therefore, it is best classified as an AGM Information announcement or related notice. However, since it is a submission of the published notice and voting information, it aligns most closely with AGM Information (AGM-R) filings, which cover presentations and materials shared during the AGM process, including notices and voting details.
2018-09-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (2221 characters) addressed to stock exchanges (BSE and NSE) regarding the submission of a published notice of the 3rd Annual General Meeting (AGM), e-voting information, and book closure dates. It includes details about the e-voting period, record date, and book closure for the AGM scheduled on September 25, 2018. The document is essentially an announcement of the AGM notice publication and related voting logistics, not the AGM materials or minutes themselves. It does not contain financial data or detailed report content. According to the 'Menu vs Meal' rule, such a short document announcing the notice and voting information is classified as Regulatory Filings (RNS) rather than AGM Information (AGM-R) or other report types.
2018-09-04 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is a communication from LASA Supergenerics Limited addressed to stock exchanges (BSE and NSE) regarding a newspaper advertisement. The content includes a statement of unaudited financial results for the quarter ended 30th June 2018, which indicates it is a quarterly financial disclosure. The document is about the publication of financial results in a newspaper, which is a common practice for interim or quarterly reports in India. The length of the document (15,000 characters) and the presence of actual financial data (unaudited financial results) suggest it is a substantive financial report rather than a mere announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2018-08-21 English
Outcome of Board Meeting
Regulatory Filings
2018-08-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.